Brain Tumor Drugs Market Forecasts from 2023 to 2028

The brain tumor drugs market is estimated to grow at a CAGR of 16.61% during the forecast period.

A brain tumor can be life-threatening if left untreated and causes nausea, headache, loss of sensation, and much more. The rising case of brain tumors worldwide coupled with the growing aging population is expected to boost the brain tumor drugs market. Moreover, various awareness programs pushing people to get treatment and research projects for enhanced treatment facilities are impacting the brain tumor drug market positively. Additionally, the increased exposure to radiation devices led to a rise in brain tumor cases thereby propelling the brain tumor drugs market.

Market Drivers

Rising Prevalence of Brain Tumor

The cases of brain tumors are on the rise due to genetic factors and family history propelling the brain tumor drug market. According to the American Society of Clinical Oncology (ASCO), an estimated 308, 102 people globally were diagnosed with primary brain tumors or spinal cord tumors in 2020. The relative survival rate of brain tumors is almost 36% as per the ASCO study. Around 1 million Americans are living with primary brain tumors in 2022 as per the National Brain Tumor Society. The prevalence of brain tumors and their life-threatening side effects are driving the brain tumor drug market.

Aging Population

Aged people are more prone to brain tumors and it can be life-threatening in most cases. For instance, the 5-year survival rate for people aged 40 or above is just 21% whereas the survival rate of younger people aged between 15 years and 39 years is almost 72% as per the ASCO study. The growing aging population is developing more brain tumor cases. For instance, one in six people will be aged 60 years or above by 2030 according to the WHO. According to Mayo Clinic, the average age of brain tumor diagnosis is 64 years which makes elderly persons more prone to brain tumors. The aging factor and the growing population are anticipated to drive the brain tumor drugs market during the forecasted period.

Growing Exposure to Chemicals and Radiation

People are getting more exposure to radiation devices and chemicals thereby increasing the chance of developing brain tumors. Earlier brain treatments with ionizing radiation including X-rays may prove to be a risk factor for developing brain tumors. WHO recommends limiting cell phone usage for both adults and children for reduced electromagnetic fields. With more people using smartphones and getting exposed to radiation from smart devices, there is a high chance of rising brain tumor cases thereby widening the brain tumor drug market.

Numerous Awareness Programs

There are various awareness programs launched in the past to educate people about brain tumor that is encouraging more people for diagnostic test thereby propelling the brain tumor drug market. World Brain Tumor Day is celebrated every year on the 8th of June which was initially taken by the German Brain Tumor Association to aware people of the myths of brain tumors. Moreover, International Brain Tumor Awareness Week was launched in October 2022 to draw attention to brain tumor education and show support to brain tumor patients worldwide. Further, the National Brain Tumor Society was formed in 2008 to support brain tumor patients through fundraising events and research workshops. These various programs along with the increased number of health-conscious people are contemplated to boost the brain tumor drugs market.

Market Opportunity

There is a phenomenal growth opportunity in the brain tumor drugs market owing to a large number of people affected with brain tumors and getting detection tests. Moreover, funding for brain tumor treatment research projects also provides good growth opportunities. For instance, the National Brain Tumor Society announced the funding of up to $450, 000 over three years for projects related to Posterior Fossa A (PFA) ependymoma in May 2023. The American Brain Tumor Association provides research collaboration grants of $200, 000 every year for multi-investor and multi-institutional brain tumor research projects. Additionally, the aging population leads to more brain tumor cases thus widening the brain tumor drugs market expansion.

North America is expected to hold notable market share during the forecast period

North American region is expected to hold a significant share of the brain tumor drugs market. The factors attributing to such share are the strong presence of the healthcare system in the US leading to a higher number of diagnoses. For instance, an estimated 24, 810 US adults are expected to be diagnosed in 2023 with primary cancerous tumors of the brain and spinal cord as per the American Society of Clinical Oncology. Moreover, the reimbursement policies and FDA approvals for brain tumor drugs are further expected to boost the brain tumor drug market in the region. For instance, there are several brain tumor drugs approved by FDA such as Alymsys, Avastin, BiCNU, Carmustine, and Everolimus among others.

Brain Tumor Drug Market Players

• Novartis AG, a Switzerland-based healthcare company provides solutions for various types of cancer including brain tumors. The oncology team of the company develops a range of treatments that destroy tumors. The company provides Chimeric antigen receptor T (CAR-T) cell therapies to attack and kill tumors.
• AstraZenecais one of the leading biopharmaceutical companies providing therapies in oncology, cardiovascular, respiratory, and other rare diseases. The company provides an Immuno-Oncology platform to activate the body’s immune system and DNA Damage Response (DDR) to block cancer cells’ ability to reproduce.
• Pfizeris an innovative healthcare company that provides breakthroughs that change patients’ lives. Recently in January 2023, the company started phase 1 of a clinical trial ofPF-07799544 which is developed for brain tumor.

Market Developments

• In June 2023, Servier Group announced the considerably delayed progression of brain tumor cells through its developed drug vorasidenib. The study conducted on 331 patients showed the delayed growth of grade 2 glioma for a median of 27.7 months.
• In January 2023, Stanford University entered into collaboration with The Invus Group to develop treatments for glioblastoma. The collaboration aims to minimize the gap between scientific research and clinical care by developing a small molecule or protein drug prototype.
• In November 2021, the first-ever oncolytic virus-based immunotherapy named Teserpaturev was approved in Japan. It has a strong killing power to brain tumor cells that the virus entered into and it also kills the cells spread in other parts of the brain. It is genetically engineered with herpes simplex virus type 1.

Segmentation:

By Therapy Type

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Indication

• Pituitary Tumors
• Meningioma
• Glioblastoma
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others